Polyglactin 910 Sutures - China

Absorbable Sutures

Fosmedic's Polyglactin 910 suture is a synthetic absorbable sterile surgical suture composed of a copolymer made from 90% glycolide and 10% L-lactide

Technical Details:

Product Polyglactin 910(PGLA) Sutures

Suture Characteristics Synthetic Absorbable Surgical Suture

Suture Type Braided

Coating Polycaprolactone and Calcium Stearate

Tensile Strength 75% tensile strength is retained for 14 days and 50% till 21 days.

Absorption Time Completely absorbed in 50-70 days

USP Range USP2~USP6/0

Color Violet and Undyed

Sterilization Gamma rays of Cobalt 60.

Shelf Life 3 years

Needle Type All needle profiles conforming to USP standards.

Thread Length 45cm, 75cm, 150cm

Needle Length 13mm-50mm

Packaging In aluminium foil packages with or without needle 12 units in one box 50 boxes in one master carton

Company Contact:

• Posted By: Shanghai Xingliao Trading Co.,Ltd.

• Phone: +86-21-52826603

• Address: Room 5C,5th Floor,No.427 Nujiang North Road,Putuo District,Shanghai,China., Shanghai , Shanghai , China

• Email:

• Website: https://www.fosmedic.com

• Business Description: Shanghai Xingliao Trading Co., Ltd.(Registered Main Brand : Fosmedic? ) also known as Fosmedic is a professional supplier for manufacturing and exporting disposable medical devices.
  
  The main products include surgical sutures, surgical blades, blood transfusion bags, transfusion sets, leukocyte filters and other medical supplies.
  
  It operates several reputable manufacturing plants located in Shanghai and Jiangsu respectively.
  
  All exported products have passed the CE and ISO certification.
  
  Recently the products have been distributed to over 40 countries and regions in Asia, Europe, Middle East, Africa, Oceania, North and South America.
  
  1st Class Quality, competitive pricing policy, perfect service system, and innovative technology has helped our products to be well recognized by global medical dealers, hospitals, blood banks, labs and clinics, as well as the health ministry of many countries and the Red Cross.
  
  Looking to the future, Fosmedic will continue to shoulder its social responsibilities, paying attention to the organization of personnel and team building, integrating medical industry resources, and finally improving its core competence to accomplish its strategic target of being a first-class enterprise in the global mainstream markets.